Serum Lipoprotein Levels During Chlorthalidone Therapy
A Veterans Administration-National Heart, Lung, and Blood Institute Cooperative Study on Antihypertensive Therapy: Mild Hypertension
- Anne I. Goldman, PhD;
- Bernard W. Steele, MD;
- Harold W. Schnaper, MD;
- Annette E. Fitz, MD;
- Edward D. Frohlich, MD;
- H. Mitchell Perry Jr, MD
Abstract
In a joint Veterans Administration-National Heart, Lung, and Blood Institute study of mild hypertension, 1,012 men and women, 21 to 50 years of age and with diastolic pressure from 85 to 105 mm Hg, were randomized into two double-blind treatment groups. Subjects in the active group received chlorthalidone or chlorthalidone plus reserpine, while the other subjects received matching placebo tablets. After one year of treatment, the chlorthalidone group had increases of 10.0±1.8 (SE) mg/dL in total cholesterol level, 9.8±5.2 mg/dL in triglyceride level, and 12.6±3.4 mg/dL in low-density lipoprotein-cholesterol level above the changes in the placebo group. There was no difference in high-density lipoprotein changes between the two groups (0.1±0.8 mg/dL). The possible net effect on risk of increasing lipid values while lowering pressure in the long-term treatment of mild hypertension with thiazides or related diuretics must be further evaluated.
(JAMA 244:1691-1695, 1980)
Footnotes
-
For a complete list of participants in this study, see p 1695.
-
Reprint requests to Box 197, Division of Biometry, 1226 Mayo, University of Minnesota, Minneapolis, MN 55455 (Dr Goldman).
